Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
jumped 20.3% in the afternoon session after the company reported third-quarter results that surpassed analyst expectations for both revenue and earnings per share.
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 2.6% year on year to $249.3 million. Its GAAP loss of $0.31 per share was 3.6% above analysts’ consensus estimates.
Tandem Diabetes Care (TNDM) beat Q3 2025 earnings and revenue estimates, driving a 16% stock surge. The company reported strong sales growth and improved margins.
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 2.2% year on year to $249.3 million. Its GAAP loss of $0.31 per share was 3.6% above analysts’ consensus estimates.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
fell 5.1% in the morning session after analyst projections for its third-quarter 2025 earnings pointed to a year-on-year revenue decline.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
fell 6% in the afternoon session after investor concerns were sparked by a disappointing financial outlook from peer DexCom. DexCom, a major company in the glucose monitoring market, reported its third-quarter financial results. Although the company's earnings and revenue surpassed targets, its stock fell sharply by around 11% to 12%. The drop was triggered after company executives provided a growth forecast for 2026 that might not meet Wall Street's expectations and also signaled a lower margin forecast. This negative outlook from a key industry player appeared to create wider concerns, weighing on shares of related companies like Tandem Diabetes.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
jumped 1.6% in the afternoon session after the company announced a positive update on a clinical study for its Control-IQ system. The study, conducted in France, aimed to assess the real-world safety, performance, and quality of life benefits for individuals with Type 1 Diabetes using the system. Positive findings from such studies could increase confidence in the product's effectiveness. The move also occurred amid a favorable long-term view of the industry, with a report projecting the U.S. insulin pump market would grow to $2.58 billion by 2033, driven by rising diabetes rates and new technology. This backdrop of potential growth came even as the company faced challenges, having recently reported a revenue increase of 8.5% year-over-year but missing earnings per share estimates.
Looking back on healthcare technology stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Tandem Diabetes (NASDAQ:TNDM) and its peers.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
fell 5.5% in the afternoon session after the U.S. government opened an investigation into the national security implications of medical equipment and device imports.
Growth boosts valuation multiples, but it doesn’t always last forever.
Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
jumped 5% in the morning session after the company announced the publication of a study showing its automated insulin delivery system was beneficial for adults with type 2 diabetes, while a broader market rally fueled by a Federal Reserve interest rate cut also provided a tailwind.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions.
While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.
